Brought to you by 
Cytyc buys Adeza for $452mm in cash
05 Mar 2007
Executive Summary
Cytyc (women's health care and cancer diagnostics) has agreed to acquire Adeza (obstetric tests and drugs) for about $452mm, or about $24 per Adeza common share (a 54% premium).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cytyc buys Adeza for $452mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice